GPRC5D car-t cell therapy for relapsed or refractory plasma cell disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy called GPRC5D CAR-T for people with multiple myeloma or other plasma cell cancers that have come back or stopped responding to treatment. The therapy uses your own immune cells to attack cancer cells that have a specific marker called GPRC5D, aiming to stop the disease from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma, plasma cell leukemia, or a similar plasma cell disorder that has returned or not responded to previous treatments.
- Your cancer cells have been tested and found to have the GPRC5D protein on their surface.
- You have already tried a stem cell transplant (using your own or donor cells) and it did not work.
- You are between 14 and 75 years old.
- Your heart, lungs, kidneys, and liver are working well enough based on blood tests and scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a CAR T-cell treatment made to find a specific marker called GPRC5D on myeloma (or plasma cell leukemia) cells. It may help people whose disease has returned or hasn’t responded to several prior treatments.
This Phase 1 trial tests a CAR T-cell treatment made to target a protein called GPRC5D on myeloma cells. It may help patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to prior treatments.
This trial tests a new car-t cell therapy called CT071 that targets a protein called GPRC5D on myeloma cells. It is for patients whose multiple myeloma or plasma cell leukemia has come back or stopped responding to previous treatments.
This trial tests a new type of CAR-T cell therapy that targets a protein called GPRC5D on multiple myeloma cells. It is for people whose myeloma has not responded to or has returned after at least three prior treatments, and aims to see if this targeted approach can help control the disease.
This trial tests a new type of cell therapy (CAR-T cells) that targets a protein called GPRC5D on myeloma cells. It is for people with multiple myeloma that has come back or not responded to several prior treatments, including immunomodulators, proteasome inhibitors, and anti-CD38 antibodies.
This trial tests a new kind of immunotherapy that uses your own immune cells, called CAR-T cells, to target two specific markers (BCMA and GPRC5D) found on myeloma cells. It's for people whose multiple myeloma has come back or stopped responding to earlier treatments.
Hear when a new Plasma Cell Dyscrasias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.